source
- Epkinly shows 51% lower risk of progression in frontline DLBCL trial, boosting hopes for expanded approvalNew Phase 3 data from the Epkinly and R-CHOP combination in diffuse large B cell lymphoma showed a 51% reduction in the risk of disease progression or death compared with standard therapy. The stud…
- Caribou Biosciences halts CAR-T programs and cuts staff amid funding shortfallCaribou Biosciences, a CRISPR gene-editing company co-founded by Nobel laureate Jennifer Doudna, announced it will stop work on its off-the-shelf CAR-T cancer therapies. The decision follows the c…